Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Liuying Township, Taiwan Clinical Trials

A listing of Liuying Township, Taiwan clinical trials actively recruiting patients volunteers.

Found (2170) clinical trials

Cabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory Multiple Myeloma

In the currently proposed phase I/II study, the investigators aim to treat patients with relapsed and/or relapsed refractory multiple myeloma (MM) who have progressed on carfilzomib-based therapy with an FDA approved c-MET inhibitor, cabozantinib. Our hypothesis is that the additional rescue blockade with cabozantinib added to the carfilzomib will (1) …

Phase

A Study to Evaluate the Safety Tolerability PK PD and Clinical Activity of EQ001 in Subjects With aGVHD

The study will enroll approximately 84 subjects in two (2) parts: Part A is an open label study and will enroll approximately 24 evaluable subjects with aGVHD across 4 cohorts. The total number of patients will depend on the number of dose escalations necessary to enable a decision to be …

Phase

Phase I Nab-Paclitaxel Plus Gemcitabine With Proton Therapy for Locally Advanced Pancreatic Cancer (LAPC)

The investigators propose a phase I trial to determine the maximum tolerable dose (MTD) and the recommended dose for phase II (RP2D) of concurrent nab-paclitaxel + gemcitabine in combination with ablative IMPT delivered as a fixed dose of 67.5 Gy in 15 fractions daily fractions with 5 fractions per week. …

Phase

Dabrafenib Trametinib and Navitoclax in Treating Patients With BRAF Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

PRIMARY OBJECTIVES: I. To determine the maximum tolerated dose (MTD), toxicity, and safety profile of navitoclax when given in combination with dabrafenib and trametinib in patients with BRAF-mutant solid tumors. (Phase I) II. To estimate the complete response (CR) rate in patients with BRAF-mutant melanoma treated with dabrafenib, trametinib, and …

Phase

Glutaminase Inhibitor CB-839 Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage IV Non-small Cell Lung Cancer

PRIMARY OBJECTIVES: I. To assess the safety and tolerability of osimertinib (AZD9291) and glutaminase inhibitor CB-839 hydrochloride (CB-839 HCl) (telaglenastat) and determine the recommended phase II dose (RP2D) in patients with metastatic, EGFR activating mutation-positive non-small cell lung cancer (NSCLC). (Phase I) II. To determine the efficacy of AZD9291 and …

Phase

Early Phase Human Drug Trial to Investigate Dynamin 101 (DYN101) in Patients 16 Years With Centronuclear Myopathies

There are no available treatments aside from supportive care for patients with Centronuclear myopathy (CNM). This trial will assess the safety, tolerability, PK and PD/preliminary efficacy of DYN101 in patients 16 years of age with CNM caused by mutations in DNM2 or MTM1. DYN101 is a synthetically manufactured constrained ethyl …

Phase

Repurposing Bromocriptine for Abeta Metabolism in Alzheimer's Disease

To investigate the safety and efficacy of an orally administered dose of TW-012R in patients with Alzheimer's disease bearing PSEN1 (presenilin 1) mutations (PSEN1-AD), using a placebo group as a control. In addition, long-term safety will be examined in an open-label extension trial.

Phase

Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C)

Substudy 02C is part of a larger research study that is testing experimental treatments for melanoma, a type of skin cancer. The larger study is the umbrella study. The goal of substudy 02C is to evaluate the safety and efficacy of investigational treatment arms in participants with Stage III melanoma …

Phase

AAV2/8-LSPhGAA in Late-Onset Pompe Disease

This study will be a prospective, open-label trial designed to objectively assess the safety and bioactivity of AAV2/8-LSPhGAA in subjects diagnosed with Pompe disease, which is caused by a defect in acid -glucosidase (GAA) gene. AAV2/8-LSPhGAA is intended to enable expression of a functional copy of the GAA gene in …

Phase

Study of CM4620 to Reduce the Severity of Pancreatitis Due to Asparaginase

This is an open label safety and efficacy evaluation with comparison of toxicity to a historical control population (TOTXVI).There will be 3 cohorts of patients enrolled, and the dose for each cohort will be determined based on the toxicities experienced in the ongoing and prior cohorts. An initial 9 patients …

Phase